Stepwise Lactate Kinetics in Critically Ill Patients: Prognostic, Influencing Factors, and Clinical Phenotype

Bo Tang  
Peking Union Medical College Hospital

Longxiang Su  
Peking Union Medical College Hospital

Dongkai Li  
Peking Union Medical College Hospital

Ye Wang  
Peking Union Medical College School of Basic Medicine Department of Epidemiology and Biostatistics: Chinese Academy of Medical Sciences Institute of Basic Medical Sciences Department of Epidemiology and Biostatistics

Qianqian Liu  
Peking Union Medical College School of Basic Medicine Department of Epidemiology and Biostatistics: Chinese Academy of Medical Sciences Institute of Basic Medical Sciences Department of Epidemiology and Biostatistics

Guangliang Shan  
Peking Union Medical College School of Basic Medicine Department of Epidemiology and Biostatistics: Chinese Academy of Medical Sciences Institute of Basic Medical Sciences Department of Epidemiology and Biostatistics

Yun Long  
Peking Union Medical College Hospital

Dawei Liu  
Peking Union Medical College Hospital

Xiang Zhou  
(✉ zx_pumc@163.com)  
Peking Union Medical College Hospital

Research article

Keywords: hyperlactatemia, lactate kinetics, clinical phenotype, fluid balance, vasopressor

Posted Date: September 25th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-74232/v1
Abstract

**Purpose:** To investigate the optimal target of lactate kinetics at different time during the resuscitation, the factors that influence whether the kinetics achieve the goals, and the clinical implications of different clinical phenotypes.

**Methods:** Patients with hyperlactatemia between May 1, 2013 and December 31, 2018 were retrospectively analyzed. Demographic data, basic organ function, hemodynamic parameters at ICU admission (T0) and at 6 h, 12 h, 24 h, 48 h, and 72 h, arterial blood lactate and blood glucose levels, cumulative clinical treatment conditions at different time points and final patient outcomes were collected.

**Results:** A total of 3298 patients were enrolled, and the mortality rate was 12.2%. The cutoff values of lactate kinetics for prognosis at 6 h, 12 h, 24 h, 48 h, and 72 h were 21%, 40%, 57%, 66%, and 72%. The APACHE II score, SOFA score, heart rate (HR), and blood glucose were risk factors that influenced whether the lactate kinetics attained the target goal. Based on the patterns of the lactate kinetics, eight clinical phenotypes were proposed. The odds ratios of death for clinical phenotypes VIII, IV, and II were 4.39, 4.2, and 5.27-fold of those of clinical phenotype I, respectively.

**Conclusion:** Stepwise recovery of lactate kinetics is an important resuscitation target for patients with hyperlactatemia. The APACHE II score, SOFA score, HR, and blood glucose were independent risk factors that influenced achievement of lactate kinetic targets. The clinical phenotypes of stepwise lactate kinetics are closely related to the prognosis.

Introduction

Hyperlactatemia is a presentation of common homeostasis disorders in critically ill patients and is closely associated with infection, stress, tissue ischemia and hypoxia, and organ dysfunction. Recent studies have indicated that elevation of blood lactate is still an independent risk factor for the intensive care unit (ICU)/hospital mortality rate of critically ill patients\(^1\)\(^{-}\)\(^4\). Based on this information, further studies showed that blood lactate dynamics, i.e., lactate kinetics, were more meaningful for disease risk stratification under different pathophysiological conditions\(^5\) and were more closely associated with prognosis\(^6\) than lactate absolute values.

Although lactate kinetics have stronger implications regarding clinical guidance than the lactate absolute value, unfortunately, in results from previous studies, the time range of lactate kinetics and the metabolism cutoff values are not consistent. For example, in a sepsis-related study, the lactate kinetics goal at 6 h was 10–34%, which is a large range\(^7\). As a dynamic indicator, lactate kinetics can not only be used for monitoring but also, more importantly, guide clinical treatment. Many previous studies have confirmed the influence of lactate kinetics on resuscitation\(^8\),\(^9\). Our previous studies also showed that compared to central venous oxygen saturation (ScvO\(_2\))-oriented hemodynamic therapy, lactate kinetics-
oriented therapy could reduce the mortality of patients with sepsis-associated hyperlactatemia\textsuperscript{10}. This study further explored the cutoff values for lactate kinetics at different time points and their influence on the mortality rate, analyzed the factors that influence the achievement of target lactate kinetics, and proposed the significance of different clinical phenotypes of stepwise lactate kinetics.

**Methods**

**Patient sample**

By examining the administrative database of Peking Union Medical College Hospital, patients with hyperlactatemia (arterial blood lactate > 4.0 mmol/L) who were hospitalized and treated in the ICU of Peking Union Medical College Hospital between May 1, 2013 and December 31, 2018 were retrospectively analyzed. The Institutional Research and Ethics Committee of Peking Union Medical College Hospital approved this study using human subjects.

**Data collection**

Arterial blood samples were collected and measured using an ABL blood gas analyzer (ABL90 FLEX, radiometer medical, Copenhagen, Denmark) within 1 min to obtain the blood lactate value. The time point of the first blood lactate result > 4.0 mmol/L in the ICU was set as T0. Demographic data, basic organ function, hemodynamic indicators and blood glucose levels at T0 and 6, 12, 24, 48, and 72 h after T0, cumulative clinical treatment conditions at different time points (fluid balance, doses of vasoactive and inotropic drugs, and amount of blood transfusion), and the final patient outcome were collected. The primary endpoint was all-cause mortality. The lactate kinetics at different time points were defined as follows: \( \text{lactate kinetics}_{TX} = \frac{(\text{lactate}_{T0} - \text{lactate}_{TX})}{\text{lactate}_{T0}} \times 100\% \). Regarding the sequence parameters, only parameters for which data were available for all time points were collected.

**Statistical analysis**

Data analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc., Cary, NC, USA). Continuous variables are expressed as the mean ± standard deviation. Variables with a normal distribution were compared using an independent sample t test. Data with an abnormal distribution are expressed as the median (interquartile range) and were compared using the Mann-Whitney U test. A two-sided value of \( P < 0.05 \) indicated a significant difference. Receiver operating characteristic (ROC) curves of lactate kinetics at different time points were constructed, and the area under the ROC curve (AUC) for predicting all-cause mortality was calculated. Based on the maximum value (\( j \)) (i.e., sensitivity + specificity - 1) of Youden's index, the best cutoff values for the above variables were confirmed. Factors (including clinical treatment conditions) associated with lactate kinetic targets at time points T6-T24 were screened using univariate and multivariate analyses. The clinical phenotypes of lactate kinetics were classified according to whether the lactate kinetic goals at 6 h, 12 h, and 24 h were attained. Logistic regression analyses were performed with death as the outcome to assess the odds ratios for different clinical phenotypes of lactate kinetics.
Results

A total of 3298 patients, with 10,949 lactate measurements, were selected for this study. There were 1695 male patients, accounting for 51.3% of the enrolled patients. The average Acute Physiology and Chronic Health Evaluation (APACHE) II score was $17.56 \pm 8.49$ points, and the average Sequential Organ Failure Assessment (SOFA) score was $8.29 \pm 4.33$ points. A total of 402 patients died, and the mortality rate was 12.2%. The detailed baseline data are shown in Table 1.
| Number of patients          | 3298 |
|----------------------------|------|
| Sex (male, patients/%)     | 1695 (51.3) |
| Age (years)                | 56.58 ± 16.26 |
| Department                 |       |
| Emergency department (patients/%) | 14 (0.43) |
| Internal medicine department (patients/%) | 318 (9.64) |
| Surgical department (patients/%) | 2535 (76.86) |
| Other hospital             | 431 (13.07) |
| Major disease              |       |
| Circulatory (patients/%)   | 646 (19.6%) |
| Respiratory (patients/%)   | 302 (9.2%) |
| Digestive (patients/%)     | 763 (23.1%) |
| Nervous system (patients/%) | 189 (5.7%) |
| Endocrine (patients%)      | 214 (6.5%) |
| Immunological (patients/%) | 81 (2.5%) |
| Kidney (patients/%)        | 119 (3.6%) |
| Bone (patients/%)          | 208 (6.3%) |
| Blood patients/%           | 37 (1.1%) |
| Other (patients/%)         | 739 (22.4%) |
| APACHE II                  | 17.56 ± 8.49 |
| SOFA                       | 8.29 ± 4.33 |
| Baseline circulation       |       |
| CVP (mmHg)                 | 9.17 ± 3.79 |
| HR (bpm)                   | 97.49 ± 20.97 |
| SBP (mmHg)                 | 135.22 ± 25.89 |

APACHE II: Acute Physiology and Chronic Health Evaluation; SOFA: sequential organ failure assessment; CVP: central venous pressure; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure, ScvO₂: central venous oxygen saturation; Pcv-aCO₂: central venous-to-arterial blood carbon dioxide partial pressure difference; Lac: lactate; Glu: blood glucose.
| Number of patients          | 3298 |
|----------------------------|------|
| DBP (mmHg)                 | 70.90 ± 14.55 |
| MAP (mmHg)                 | 92.69 ± 18.36 |
| ScvO₂ (%)                  | 75.27 ± 11.37 |
| Pcv-aCO₂ (mmHg)            | 5.85 ± 3.43  |
| Lac (mmol/L)               | 6.22 ± 3.15  |
| Glu (mmol/L)               | 11.56 ± 3.83 |

APACHE II: Acute Physiology and Chronic Health Evaluation; SOFA: sequential organ failure assessment; CVP: central venous pressure; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; ScvO₂: central venous oxygen saturation; Pcv-aCO₂: central venous-to-arterial blood carbon dioxide partial pressure difference; Lac: lactate; Glu: blood glucose.

Regarding hemodynamic indicators, central venous pressure (CVP), heart rate (HR), and lactate showed a gradual decreasing trend, with significant differences over time (Table 2). The lactate kinetics cutoff values for different time points are shown in Table 3 and Fig. 1. The lactate kinetics value at 6 h was 21%, and at 12 h, 24 h, 48 h, and 72 h, the lactate kinetics values were 40%, 57%, 66%, and 72%, respectively. The obtained cutoff values for T6, T12, and T24 lactate kinetics in this study were used to define target achievement when these cutoff values were met. Analyses were performed using unachieved targets as the outcome. Therefore, the APACHE II score, SOFA score, HR, and blood glucose were risk factors for goal achievement at different timepoints (Table 4).
Table 2

|     | n     | T0       | T6       | T12      | T24      | T48      | T72      | P     |
|-----|-------|----------|----------|----------|----------|----------|----------|-------|
| CVP | 549   | 9.75 ± 3.8 | 9.7 ± 3.15 | 9.64 ± 2.91 | 9.41 ± 2.74$ | 8.96 ± 2.83& | 8.27 ± 3.11% | < 0.0001 |
| HR  | 1104  | 102.49 ± 20.65 | 100.75 ± 19.11* | 99.37 ± 18.03# | 98.57 ± 17.15$ | 95.71 ± 17.43& | 92.35 ± 16.34% | < 0.0001 |
| SBP | 966   | 132.36 ± 24.49 | 130.04 ± 19.23* | 131.65 ± 19.26 | 131.09 ± 20.06 | 132.7 ± 20.4 | 133.17 ± 20.93 | 0.001 |
| DBP | 965   | 68.63 ± 14.43 | 68.44 ± 12.06 | 68.79 ± 11.73 | 68.7 ± 12.7 | 69.26 ± 12.36 | 68.76 ± 12.04 | 0.5346 |
| MAP | 963   | 89.68 ± 17.46 | 88.2 ± 12.68* | 88.86 ± 12.38 | 88.99 ± 13.21 | 89.96 ± 13.41 | 89.9 ± 14.08 | 0.0079 |
| ScvO₂| 576   | 75.15 ± 11.68 | 74.53 ± 9.24 | 74.8 ± 8.7 | 74.21 ± 8.86 | 73.45 ± 9.26& | 72.76 ± 9.42% | < 0.0001 |
| Pcv-aCO₂| 695 | 5.59 ± 3.41 | 5.53 ± 3.02 | 5.09 ± 2.75# | 4.72 ± 2.74$ | 5 ± 3.17& | 5.17 ± 3.2% | < 0.0001 |
| Lac | 1179  | 6.89 ± 3.44 | 5.56 ± 3.93* | 3.86 ± 3.33# | 2.56 ± 2.38$ | 1.98 ± 2.27& | 1.83 ± 2.6% | < 0.0001 |

*significant difference between T6 and T0; #significant difference between T12 and T0; $significant difference between T24 and T0; %significant difference between T48 and T0; $significant difference between T72 and T0; P < 0.05. CVP: central venous pressure; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; ScvO₂: central venous oxygen saturation; Pcv-aCO₂: central venous-to-arterial blood carbon dioxide partial pressure difference; Lac: lactate

Table 3

| Lactate kinetics | Best cutoff point | Sensitivity | Specificity | Youden's index | AUC   |
|------------------|-------------------|-------------|-------------|----------------|-------|
| T6               | 0.21              | 0.624       | 0.665       | 0.2894         | 0.684 |
| T12              | 0.40              | 0.685       | 0.742       | 0.4271         | 0.768 |
| T24              | 0.57              | 0.737       | 0.779       | 0.5161         | 0.818 |
| T48              | 0.66              | 0.774       | 0.806       | 0.5801         | 0.848 |
| T72              | 0.72              | 0.763       | 0.753       | 0.5165         | 0.831 |
Table 4
Influencing factors of the group that did not achieve lactate kinetics targets at timepoints T6-T24

|                     | Univariate |           |         | Multivariate |           |         |
|---------------------|------------|-----------|---------|--------------|-----------|---------|
|                     | OR (95% CI)| P         | OR (95% CI) | P         |
| Age (every 10 years vs. <20 years) | 1.05 (1, 1.1) | 0.0604 | 1.05 (0.98, 1.12) | 0.1877 |
| Sex (male vs. female) | 1.07 (0.93, 1.24) | 0.3421 | 0.83 (0.67, 1.02) | 0.076 |
| APACHE II score (T0, every 5 points vs. <5 points) | 1.35 (1.29, 1.42) | < 0.0001 | 1.23 (1.14, 1.32) | < 0.0001 |
| SOFA score (T0, every 5 points vs. <5 points) | 1.66 (1.52, 1.82) | < 0.0001 | 1.21 (1.05, 1.4) | 0.0103 |
| Heart rate (T6, every 10 bpm vs. <60 bpm) | 1.22 (1.17, 1.27) | < 0.0001 | 1.11 (1.04, 1.18) | 0.0017 |
| Invasive average blood pressure (T6, every 10 mmHg vs. <60 mmHg) | 0.93 (0.88, 0.99) | 0.0136 | 0.97 (0.9, 1.05) | 0.4918 |
| SvO₂ (T6) | 0.99 (0.98, 1) | 0.1163 | 1.01 (1, 1.03) | 0.0236 |
| Pcv-aCO₂ (T6) | 1.04 (1.02, 1.07) | 0.0026 | 1.07 (1.03, 1.11) | 0.0004 |
| Blood glucose (T6) | 1.15 (1.12, 1.18) | < 0.0001 | 1.12 (1.09, 1.15) | < 0.0001 |
| Age (every 10 years vs. <20 years) | 1.04 (0.98, 1.09) | 0.2061 | 1.04 (0.96, 1.12) | 0.3768 |
| Sex (male vs. female) | 1.06 (0.9, 1.26) | 0.4693 | 0.98 (0.77, 1.24) | 0.8532 |
| APACHE II score (T0, every 5 points vs. <5 points) | 1.48 (1.39, 1.56) | < 0.0001 | 1.27 (1.17, 1.38) | < 0.0001 |
| SOFA score (T0, every 5 points vs. <5 points) | 2.1 (1.88, 2.35) | < 0.0001 | 1.48 (1.24, 1.76) | < 0.0001 |
|                               | Univariate                        |          |          | Multivariate                    |          |
|-------------------------------|-----------------------------------|----------|----------|---------------------------------|----------|
|                               | OR (95% CI)                       | P        | OR (95% CI) | P                                |          |
| Heart rate (T12, every 10 bpm vs. <60 bpm) | 1.26 (1.2, 1.33)                  | < 0.0001 | 1.12 (1.04, 1.21) | 0.0029                           |          |
| Invasive average blood pressure (T6, every 10 mmHg vs. <60 mmHg) | 0.95 (0.89, 1.02)                  | 0.1325   | 1.02 (0.93, 1.12) | 0.6621                           |          |
| SvO2 (T12)                    | 0.99 (0.98, 1)                    | 0.0164   | 1.01 (1, 1.03) | 0.0864                           |          |
| Pcv-aCO2 (T12)                | 1.02 (0.99, 1.05)                 | 0.2596   | 1.05 (1, 1.09) | 0.0365                           |          |
| Blood glucose (T12)           | 1.19 (1.15, 1.23)                 | < 0.0001 | 1.15 (1.1, 1.2) | < 0.0001                         |          |
| T24                           | Age (every 10 years vs. <20 years) | 1.1 (1.04, 1.17) | 0.0016   | 1.04 (0.94, 1.14) | 0.4542                           |          |
|                               | Sex (male vs. female)             | 1.09 (0.9, 1.32) | 0.3677   | 0.86 (0.65, 1.14) | 0.2994                           |          |
|                               | APACHE II score (T24, every 5 points vs. <5 points) | 1.51 (1.41, 1.61) | < 0.0001 | 1.27 (1.15, 1.39) | < .0001                          |          |
|                               | SOFA score (T24, every 5 points vs. <5 points) | 1.91 (1.66, 2.21) | < 0.0001 | 1.78 (1.44, 2.19) | < .0001                          |          |
|                               | Heart rate (T24, every 10 bpm vs. <60 bpm) | 1.25 (1.17, 1.34) | < 0.0001 | 1.15 (1.04, 1.26) | 0.0041                           |          |
|                               | Invasive average blood pressure (T24, every 10 mmHg vs. <60 mmHg) | 1.02 (0.94, 1.1) | 0.6136   | 1.09 (0.98, 1.21) | 0.1225                           |          |
|                               | Pcv-aCO2 (T24)                    | 0.99 (0.98, 1) | 0.0833   | 1 (0.99, 1.02) | 0.8153                           |          |
|                               | Pcv-aCO2 (T24)                    | 1.01 (0.97, 1.04) | 0.7441   | 0.99 (0.94, 1.05) | 0.8095                           |          |
|                               | Blood glucose (T24)               | 1.1 (1.06, 1.14) | < 0.0001 | 1.06 (1, 1.13) | 0.0413                           |          |
Stratification was performed based on an APACHE II score of < 15 or ≥ 15 to further compare factors that influence achievement of lactate kinetics targets at different timepoints. The results showed that for patients with severe disease conditions (APACHE II score ≥ 15), the positive fluid balance and the norepinephrine dose for patients in the group that achieved lactate kinetics targets were significantly lower than those in the group that did not achieve the targets (Table 5).
|                | Unachieved | Achieved | P*       |
|----------------|------------|----------|----------|
|                | n          | Median (P25, P75) | n          | Median (P25, P75) |       |
|                |            |           |           |               |       |
| **T6**         |            |           |           |               |       |
| **APACHE II score T0 < 15** |            |           |           |               |       |
| Fluid balance  | 352        | 218.3 (-92.8, 626.58) | 907        | 140 (-204, 562) | 0.0450 |
| Norepinephrine dose | 2       | 8.5 (6, 11)          | 12         | 6.5 (3, 16)     | 0.9270 |
| Adrenaline dose | 0         | 0                    | 0          | 0               |        |
| Milrinone dose  | 0         | 0                    | 0          | 0               |        |
| Dobutamine dose | 0         | 0                    | 0          | 0               |        |
| **APACHE II score T0 ≥ 15** |            |           |           |               |       |
| Fluid balance  | 679        | 704.4 (86, 1341.85)  | 886        | 320.43 (-129.8, 879.6) | < 0.0001 |
| Norepinephrine dose | 156      | 24 (12, 71)          | 60         | 12.5 (4, 25.5)  | < 0.0001 |
| Adrenaline dose | 36        | 11.5 (4, 20.5)       | 7          | 6 (2, 6)        | 0.2613 |
| Milrinone dose  | 24        | 5700 (2000, 8250)    | 15         | 3000 (1200, 7200) | 0.3615 |
| Dobutamine dose | 10        | 50 (30, 110)         | 9          | 40 (10, 60)     | 0.2838 |
| **T12**        |            |           |           |               |       |
| **APACHE II score T0 < 15** |            |           |           |               |       |
| Fluid balance  | 184        | 271.55 (-226.85, 728.05) | 779        | 166.9 (-339.65, 684.3) | 0.1744 |
| Norepinephrine dose | 4       | 12.5 (7.5, 18)       | 12         | 6 (2.5, 30)     | 0.6708 |
| Adrenaline dose | 0         | 0                    | 0          | 0               |        |
| Milrinone dose  | 1         | 11000 (11000, 11000) | 6          | 9500 (3000, 14400) | 0.8026 |
| Dobutamine dose | 1         | 180 (180, 180)       | 5          | 40 (10, 70)     | 0.5525 |
| **APACHE II score T0 ≥ 15** |            |           |           |               |       |
| Fluid balance  | 499        | 874.95 (-15.95, 2121.7) | 816        | 386.35 (-259.9, 1099.14) | < 0.0001 |
A total of 1919 patients with complete lactate kinetics data within 24 h were divided into achieved and unachieved groups using the best cutoff point for the ROC curve for achievement of the target within 24 h, and their clinical phenotype groups were plotted using the assigned values. All-cause mortality was used as the outcome. Based on the pattern of the timepoint achievements, eight clinical phenotypes were proposed (Table 6 – 1). Analyses of the influencing factors showed that when the goals at all timepoints were unachieved, the odds ratios of death increased by 4.39-fold (clinical phenotype VIII). When the lactate kinetics targets at 6 h were attained and at those at 12 and 24 h were not attained (clinical phenotype IV) or when the 24 h lactate kinetics target was not attained (clinical phenotype II), the odds ratios increased (Table 6 – 2).

|                   | Unachieved | Achieved | P*       |
|-------------------|------------|----------|----------|
|                   | n          | Median (P25, P75) | n | Median (P25, P75) |
| Norepinephrine dose | 157 | 37 (18, 88) | 57 | 17 (7, 32) | < 0.0001 |
| Adrenaline dose    | 34 | 15 (7, 42) | 8 | 7 (1, 16.5) | 0.0628 |
| Milrinone dose     | 24 | 4400 (1000, 10000) | 22 | 9300 (2000, 13000) | 0.1122 |
| Dobutamine dose    | 8 | 65 (25, 185) | 9 | 80 (70, 240) | 0.3586 |

**T24**

**APACHE II score T24 < 15**

|                   | Unachieved | Achieved | P*       |
|-------------------|------------|----------|----------|
|                   | n          | Median (P25, P75) | n | Median (P25, P75) |
| Fluid balance     | 168 | 177.3 (-815.41, 1180.73) | 694 | -173.78 (-1120.7, 800.3) | 0.0127 |
| Norepinephrine dose | 24 | 18.5 (3, 44) | 34 | 11.5 (4, 24) | 0.4766 |
| Adrenaline dose    | 0 | 0 | 0 | 0 | 0.4766 |
| Milrinone dose     | 2 | 10500 (10000, 11000) | 14 | 6900 (3000, 14400) | 0.4249 |
| Dobutamine dose    | 4 | 200 (50, 530) | 4 | 40 (10, 70) | 0.3065 |

**APACHE II score T24 ≥ 15**

|                   | Unachieved | Achieved | P*       |
|-------------------|------------|----------|----------|
|                   | n          | Median (P25, P75) | n | Median (P25, P75) |
| Fluid balance     | 322 | 748.95 (-736.2, 2539.35) | 484 | 227.43 (-896.83, 1396.85) | 0.0005 |
| Norepinephrine dose | 128 | 49 (20.5, 108.5) | 62 | 17.5 (7, 44) | < 0.0001 |
| Adrenaline dose    | 25 | 29 (8, 60) | 13 | 6 (1, 7) | 0.0007 |
| Milrinone dose     | 18 | 4500 (2000, 18000) | 24 | 13500 (1600, 23000) | 0.4372 |
| Dobutamine dose    | 5 | 70 (30, 210) | 12 | 165 (80, 240) | 0.3968 |
Table 6
− 1 Lactate metabolism within 24 h (clinical phenotype groups based on whether the target was achieved or unachieved)

| T6   | T12   | T24   | Given value in the model          | Number of patients (a total of 1919 cases) |
|------|-------|-------|-----------------------------------|-------------------------------------------|
| Achieved | Achieved | Achieved | Clinical phenotype 1 (ref)       | 806                                       |
| Unachieved |       |       | Clinical phenotype 2            | 89                                        |
| Unachieved | Achieved |       | Clinical phenotype 3            | 74                                        |
| Unachieved |       |       | Clinical phenotype 4            | 79                                        |
| Unachieved | Achieved | Achieved | Clinical phenotype 5            | 298                                       |
| Unachieved |       |       | Clinical phenotype 6            | 38                                        |
| Unachieved | Achieved |       | Clinical phenotype 7            | 223                                       |
| Unachieved |       |       | Clinical phenotype 8            | 312                                       |
### Table 6

| Clinical phenotype 2 (vs. Clinical phenotype 1) | Multivariate model* OR (95% CI) | P |
|------------------------------------------------|----------------------------------|---|
| Age (every 10 years vs. <20 years)             | 1.03 (0.89, 1.2)                 | 0.6546 |
| Sex (male vs. female)                          | 0.6 (0.38, 0.93)                 | 0.0215 |
| APACHE II score (T24, every 5 points vs. <5 points) | 1.66 (1.44, 1.92)               | <0.0001 |
| SOFA score (T24, every 5 points vs. <5 points) | 2.24 (1.56, 3.22)               | <0.0001 |
| Heart rate (T24, every 10 bpm vs. <60 bpm)     | 0.9 (0.78, 1.03)                 | 0.1253 |
| Invasive average blood pressure (T24, every 10 mmHg vs. <60 mmHg) | 0.8 (0.68, 0.94)               | 0.0062 |
| SvO₂ (T24)                                     | 0.98 (0.96, 1)                  | 0.0767 |
| Pcv-aCO₂ (T24)                                 | 0.91 (0.84, 0.99)               | 0.0273 |
| Blood glucose (T24)                            | 1.02 (0.94, 1.11)               | 0.5999 |

### Discussion

This study retrospectively analyzed changes in the lactate kinetics of patients with hyperlactatemia and showed that lactate kinetics at 6 h, 12 h, 24 h, 48 h, and 72 h were 21%, 40%, 57%, 66%, and 72%, respectively. Using these values as standards, their predictive value for patient death gradually increased (AUC 0.684–0.848). Examination of the factors that influenced achieving 6 h, 12 h, and 24 h lactate kinetics targets showed that the APACHE II score, SOFA score, HR, and blood glucose were independent risk factors at the time points that we measured. These results suggest that disease severity and the level of organ dysfunction affect the ability to achieve lactate kinetics targets. After stratification using the APACHE II score, the results showed that in critically ill patients (APACHE II ≥ 15), appropriate fluid balance and norepinephrine doses were beneficial for achieving lactate kinetics targets, whereas
excessive positive fluid balance and large norepinephrine doses were harmful. Additionally, the effects of continuously achieving lactate kinetics targets on the prognosis were further analyzed and classified into eight clinical phenotypes. The results showed clinical phenotype VIII (T6, T12, and T24 targets were unachieved) had the highest odds ratio of patient death (OR = 4.39; 95% CI 2.4–8.03). Even when the lactate kinetics target was achieved at 6 h but not at the following timepoints (clinical phenotype IV and II), the odds ratio still increased (OR = 4.2; 95% CI 1.69–10.48 and OR = 5.27; 95% CI 2.33–11.88, respectively).

Although some studies have explored the relationship between lactate kinetics and the prognosis of critically ill patients, some key issues, such as (1) the optimal cutoff value of lactate kinetics at different times and (2) the appropriate duration of monitoring lactate kinetics, remain unclear. To solve these problems, we first reviewed and analyzed the optimal cutoff value for prognosis at different timepoints. The results showed that the optimal cutoff values corresponding to these time points increased gradually. The EMShockNet investigators reported noninferiority in terms of reduction in hospital mortality among the group with lactate kinetics greater than 10% at 6 h and in the group with ScvO\textsubscript{2} ≥ 70% at 6 h (17% vs 23%) \textsuperscript{11}. Craig et al. reported in a retrospective study that resuscitation within 6 h and lactate kinetics of 36% could predict the prognoses of patients with sepsis\textsuperscript{12}. Maryna et al. reported that lactate kinetics \textsubscript{T24h} ≤ 19% was associated with increased ICU mortality (15% vs 43%; OR 4.11)\textsuperscript{13}. In addition to the specific cutoff value differences, our results are consistent with previous studies because, on the one hand, the sample size of these studies is different; on the other hand, the prognosis and lactate kinetics of critically ill patients are closely related to disease heterogeneity and treatment differences in different centers\textsuperscript{14,15}. From the lessons learned from the failure of studies on supernormal goal-oriented therapy in the last century, we realized the importance of setting reasonable resuscitation goals\textsuperscript{16,17}. In fact, recovery of organ function, tissue perfusion, and even cell function during resuscitation requires time. Reasonable lactate kinetic goals can both produce the internal driving force to promote resuscitation and meet the physiological needs of the body to avoid excessive therapy caused by inappropriate and excessively high goals.

For patients with hyperlactatemia, how long should we monitor the lactate kinetics? Hernandez et al.\textsuperscript{18} confirmed that only 52% of septic shock patients had normal blood lactate levels within 24 h. In a study by Maryna et al., for patients with lactate kinetics less than 19%, the average lactate level for the first 24 h was 5.25 mmol/L, and the average for the second 24 h was 6.43 mmol/L. Even in patients with lactate kinetics greater than 19%, the average lactate level for the first 24 h was 5.10 mmol/L, and the average for the second 24 h was 2.47 mmol/L. Thus, even after 24 h of resuscitation, a large number of patients still have hyperlactatemia and hypoperfusion. Therefore, monitoring 6 h, 12 h, or 24 h lactate kinetics alone is not sufficient to guide the entire process of resuscitation therapy. Based on the above reasons, our retrospective analysis of previous patients determined lactate kinetics cutoff values at five time points, from 6 h to 72 h. In addition, with the passage of time, the lactate kinetics gradually increased, and the ability to predict the survival rate of patients was also more evident.
Our study further examined the risk factors that influence whether the lactate kinetics at each time point reach these cutoff values. Various factors affect the achievement of lactate kinetics targets in clinical practice. Disease severity and the level of organ dysfunction are important components from our dataset. As representatives of these two aspects, the APACHE II score and SOFA score both show direct influences on achieving lactate kinetics goals, indicating that they are still reliable and indispensable evaluation tools for critically ill patients. Furthermore, additional attention should be paid to reductions in stress responses in critically ill patients, and the HR is a sensitive indicator of stress in the body. Many studies in recent years have confirmed that sepsis patients obtained excellent effects after applying β-receptor blockers to control the ventricular rate\textsuperscript{19–21} to reduce stress responses. For cardiogenic shock patients, reduction in the ventricular rate can improve ventricular diastolic function to further improve the ventricular stroke volume and overall cardiac efficiency, which is beneficial for improving tissue perfusion and the prognosis\textsuperscript{22,23}. In our study, HR was an independent risk factor for achieving lactate kinetics targets from 6 h to 24 h, which again confirms that the influence of HR on the treatment of critically ill patients requires attention. High blood glucose is also a presentation of stress responses in critically ill patients. One recent study showed that a high blood glucose level was an independent risk factor for in-hospital death of cardiogenic shock patients\textsuperscript{24}. Another study showed that, for both cardiogenic shock and septic shock, hyperlactatemia was mainly caused by an increase in lactate production and that the increase in lactate production was usually accompanied by high blood glucose and an increase in glucose turnover, indicating that the latter had great impacts on lactate metabolism\textsuperscript{25}. Our study also showed that blood glucose affected achieving lactate kinetics targets, suggesting that blood glucose control should be a focus during shock resuscitation.

After the lactate kinetics targets were confirmed, we evaluated the effects of clinical resuscitation measures on dynamic attainment. The results showed that for patients with critical illness (APACHE II score $\geq 15$ points), conservative fluid resuscitation strategies were more likely to achieve lactate kinetics targets. A meta-analysis published in 2017 confirmed that for patients with acute respiratory distress syndrome (ARDS), sepsis, or systemic inflammatory response syndrome (SIRS), a conservative fluid resuscitation strategy can reduce the mechanical ventilation time and length of ICU stay\textsuperscript{26}. Our study results further validated that conservative fluid resuscitation also had positive effects on lactate metabolism. Previous studies showed that the application of norepinephrine to increase the blood pressure of septic shock patients to 85 mmHg did not benefit tissue oxygen metabolism, skin capillary blood flow, and urine output\textsuperscript{27}. In addition, excessive norepinephrine can cause increased peripheral blood vessel contraction, resulting in microcirculation disturbances and terminal necrosis. Our study also suggested that the norepinephrine doses were lower in the group that achieved lactate kinetics targets, which is consistent with the “less is more” concept promoted in recent years\textsuperscript{28}, with an emphasis on a balance between treatment and reinjury.

By observing the change in the trajectory of lactate kinetics while reaching the cutoff values, we confirmed that the group that continuously reached the cutoff values had an obviously better outcome than that of the group that reached the cutoff values at any time point. According to these dynamic changes in lactate
kinetics, we proposed clinical phenotypes of lactate kinetics to identify the most critical points and the phenotype for the best prognosis. The effect of the previously reported 6 h lactate kinetics attainment rate on the prognosis was not as good as that of the 12 h and 24 h attainment rates, which was partially consistent with results from a previous study \(^{29}\). Clinically, the phenotype of lactate changes can be used to determine the patient prognosis. These results suggested that, under limited resource conditions, greater focus should be placed on achieving 12 and 24 h lactate kinetics goals rather than 6 h lactate kinetics goals. Additionally, attaining high lactate kinetics goals might require more fluid infusion during treatment, the application of more inotropic drugs to increase cardiac output, and setting a higher arterial pressure, which might cause harm \(^{16,17}\). The phenotype theory based on the lactate kinetics cutoff values at different timepoints represents a milestone for the entire resuscitation process; thus, the goals during resuscitation are clearer, and insufficient or excessive resuscitation can be avoided.

Our study had some limitations. First, this study was a retrospective, single-center study. The confirmed lactate kinetics cutoff values at different timepoints lack broad representation. Factors such as differences in therapeutic strategies at different medical institutions (such as blood transfusion and cardiotonic therapy) and timeliness of treatment might influence the determination of cutoff values. Therefore, a multicenter study with a clear and unified treatment plan is needed for further verification. Second, this study targeted all critically ill patients. In the future, the lactate kinetics of patients with certain diseases, such as septic shock and cardiogenic shock, can be explored according to disease classification in order to more accurately guide clinical treatment. Third, this study included a 72 h period, but some patients did not remain in the ICU for this length of time due to death and transfer out. Over time, fewer patients were included in the analysis. Therefore, we can only include all of the parameters that we can obtain, and we cannot rule out actual factors that affect the data.

**Conclusion**

Stepwise recovery of lactate kinetics is an important resuscitation target for patients with severe hyperlactatemia. The cutoff values for lactate kinetics at 6 h, 12 h, 24 h, 48 h, and 72 h that influenced patient prognosis were 21%, 40%, 57%, 66%, and 72%, respectively. The APACHE II score, SOFA score, HR, and blood glucose are independent risk factors that influenced achievement lactate kinetic targets. When the lactate clearance rate is high, additional fluid support and vasoactive drugs are not needed. Clinical phenotypes of stepwise lactate kinetics are proposed, which may contribute to assessment of the prognosis. Although our conclusions are based on a large sample size, the conclusions of this study need to be supported by prospective multicenter studies in the future.

**Declarations**

**Ethics approval and consent to participate**

The research protocol was approved by the ethics committee of Peking Union Medical College Hospital.
Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Funding

None

Authors' contributions:

Bo Tang and Longxiang Su are joint authors and contributed equally to this manuscript. Dongkai Li extracted data from database. Ye Wang, Qianqian Liu and Guangliang Shan participated in statistical guidance and analyses. Yun Long, Dawei Liu and Xiang Zhou conceived and designed the manuscript and gave final approval of the version to be published. All of the authors read and approved the final manuscript.

Acknowledgements

Not applicable

Availability of data and materials

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request

References

1. Chebl RB, Tamim H, Dagher GA, Sadat M, Al Enezi F, Arabi YM. Serum Lactate as an Independent Predictor of In-Hospital Mortality in Intensive Care Patients. J Intensive Care Med 2019:885066619854355.

2. Manikis P, Jankowski S, Zhang H, Kahn RJ, Vincent JL. Correlation of serial blood lactate levels to organ failure and mortality after trauma. Am J Emerg Med. 1995;13:619–22.

3. Mikkelsen ME, Miltiades AN, Gaiieski DF, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med. 2009;37:1670–7.

4. Lindholm MG, Hongisto M, Lassus J, et al. Serum Lactate and A Relative Change in Lactate as Predictors of Mortality in Patients With Cardiogenic Shock - Results from the Cardshock Study. Shock. 2020;53:43–9.

5. Attana P, Lazzeri C, Picariello C, Dini CS, Gensini GF, Valente S. Lactate and lactate clearance in acute cardiac care patients. Eur Heart J Acute Cardiovasc Care. 2012;1:115–21.
6. Vincent JL, Quintairos ESA, Couto L Jr, Taccone FS. The value of blood lactate kinetics in critically ill patients: a systematic review. Crit Care. 2016;20:257.

7. Han KS, Kim SJ, Lee EJ, Park KY, Lee JY, Lee SW. Impact of rapid lactate clearance as an indicator of hemodynamic optimization on outcome in out-of-hospital cardiac arrest: A retrospective analysis. PLoS One. 2019;14:e0214547.

8. Puskarich MA, Trzeciak S, Shapiro NI, et al. Prognostic value and agreement of achieving lactate clearance or central venous oxygen saturation goals during early sepsis resuscitation. Acad Emerg Med. 2012;19:252–8.

9. Arnold RC, Shapiro NI, Jones AE, et al. Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis. Shock. 2009;32:35–9.

10. Zhou X, Liu D, Su L, et al. Use of stepwise lactate kinetics-oriented hemodynamic therapy could improve the clinical outcomes of patients with sepsis-associated hyperlactatemia. Crit Care. 2017;21:33.

11. Jones AE, Shapiro NI, Trzeciak S, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010;303:739–46.

12. Walker CA, Griffith DM, Gray AJ, Datta D, Hay AW. Early lactate clearance in septic patients with elevated lactate levels admitted from the emergency department to intensive care: time to aim higher? J Crit Care. 2013;28:832–7.

13. Masyuk M, Wernly B, Lichtenauer M, et al. Prognostic relevance of serum lactate kinetics in critically ill patients. Intensive Care Med. 2019;45:55–61.

14. Paoli CJ, Reynolds MA, Sinha M, Gitlin M, Crouser E. Epidemiology and Costs of Sepsis in the United States-An Analysis Based on Timing of Diagnosis and Severity Level. Crit Care Med. 2018;46:1889–97.

15. Schultz MJ, Dunser MW, Dondorp AM, et al. Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future. Intensive Care Med. 2017;43:612–24.

16. Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370:1583–93.

17. Baigorri F, Russell JA. Oxygen delivery in critical illness. Crit Care Clin. 1996;12:971–94.

18. Hernandez G, Luengo C, Bruhn A, et al. When to stop septic shock resuscitation: clues from a dynamic perfusion monitoring. Ann Intensive Care. 2014;4:30.

19. Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310:1683–91.

20. Morelli A, Singer M, Ranieri VM, et al. Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. Intensive Care Med. 2016;42:1528–34.
21. Du W, Wang XT, Long Y, Liu DW. Efficacy and Safety of Esmolol in Treatment of Patients with Septic Shock. Chin Med J (Engl). 2016;129:1658–65.

22. Mehta RH, Califf RM, Yang Q, et al. Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. Am J Cardiol. 2007;99:793–6.

23. Levy B, Perez P, Perny J, Thivilier C, Gerard A. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med. 2011;39:450–5.

24. Kataja A, Tarvasmaki T, Lassus J, et al. The association of admission blood glucose level with the clinical picture and prognosis in cardiogenic shock - Results from the CardShock Study. Int J Cardiol. 2017;226:48–52.

25. Revelly JP, Tappy L, Martinez A, et al. Lactate and glucose metabolism in severe sepsis and cardiogenic shock. Crit Care Med. 2005;33:2235–40.

26. Silversides JA, Major E, Ferguson AJ, et al. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med. 2017;43:155–70.

27. LeDoux D, Astiz ME, Carpati CM, Rackow EC. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med. 2000;28:2729–32.

28. Auriemma CL, Van den Berghe G, Halpern SD. Less is more in critical care is supported by evidence-based medicine. Intensive Care Med 2019.

29. Ferreruela M, Raurich JM, Ayestaran I, Llompart-Pou JA. Hyperlactatemia in ICU patients: Incidence, causes and associated mortality. J Crit Care. 2017;42:200–5.

Figures
Figure 1

ROC curves of lactate kinetics at different timepoints